Literature DB >> 17404305

Dynamic relationship between IFN-gamma and IL-2 profile of Mycobacterium tuberculosis-specific T cells and antigen load.

Kerry A Millington1, John A Innes, Sarah Hackforth, Timothy S C Hinks, Jonathan J Deeks, Davinder P S Dosanjh, Valerie Guyot-Revol, Rubamalaar Gunatheesan, Paul Klenerman, Ajit Lalvani.   

Abstract

Distinct IFN-gamma and IL-2 profiles of Ag-specific CD4(+) T cells have recently been associated with different clinical disease states and Ag loads in viral infections. We assessed the kinetics and functional profile of Mycobacterium tuberculosis Ag-specific T cells secreting IFN-gamma and IL-2 in 23 patients with untreated active tuberculosis when bacterial and Ag loads are high and after curative treatment, when Ag load is reduced. The frequencies of M. tuberculosis Ag-specific IFN-gamma-secreting T cells declined during 28 mo of follow-up with an average percentage decline of 5.8% per year (p = 0.005), while the frequencies of Ag-specific IL-2-secreting T cells increased during treatment (p = 0.02). These contrasting dynamics for the two cytokines led to a progressive convergence of the frequencies of IFN-gamma- and IL-2-secreting cells over 28 mo. Simultaneous measurement of IFN-gamma and IL-2 secretion at the single-cell level revealed a codominance of IFN-gamma-only secreting and IFN-gamma/IL-2 dual secreting CD4(+) T cells in active disease that shifted to dominance of IFN-gamma/IL-2-secreting CD4(+) T cells and newly detectable IL-2-only secreting CD4(+) T cells during and after treatment. These distinct T cell functional signatures before and after treatment suggest a novel immunological marker of mycobacterial load and clinical status in tuberculosis that now requires validation in larger prospective studies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17404305      PMCID: PMC2743164          DOI: 10.4049/jimmunol.178.8.5217

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

Review 1.  Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-04       Impact factor: 21.405

Review 2.  Regimens of less than six months for treating tuberculosis.

Authors:  H Gelband
Journal:  Cochrane Database Syst Rev       Date:  2000

3.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions.

Authors:  F Sallusto; D Lenig; R Förster; M Lipp; A Lanzavecchia
Journal:  Nature       Date:  1999-10-14       Impact factor: 49.962

4.  Restoration of mycobacterial antigen-induced proliferation and interferon-gamma responses in peripheral blood mononuclear cells of tuberculosis patients upon effective chemotherapy.

Authors:  R Al-Attiyah; A S Mustafa; A T Abal; N M Madi; P Andersen
Journal:  FEMS Immunol Med Microbiol       Date:  2003-10-15

5.  Counting antigen-specific T cells: a new approach for monitoring response to tuberculosis treatment?

Authors:  Ajit Lalvani
Journal:  Clin Infect Dis       Date:  2004-02-17       Impact factor: 9.079

6.  Depressed T-cell interferon-gamma responses in pulmonary tuberculosis: analysis of underlying mechanisms and modulation with therapy.

Authors:  C S Hirsch; Z Toossi; C Othieno; J L Johnson; S K Schwander; S Robertson; R S Wallis; K Edmonds; A Okwera; R Mugerwa; P Peters; J J Ellner
Journal:  J Infect Dis       Date:  1999-12       Impact factor: 5.226

7.  Enrichment and detection of live antigen-specific CD4(+) and CD8(+) T cells based on cytokine secretion.

Authors:  H Brosterhus; S Brings; H Leyendeckers; R A Manz; S Miltenyi; A Radbruch; M Assenmacher; J Schmitz
Journal:  Eur J Immunol       Date:  1999-12       Impact factor: 5.532

8.  Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy.

Authors:  Stefania Carrara; Donatella Vincenti; Nicola Petrosillo; Massimo Amicosante; Enrico Girardi; Delia Goletti
Journal:  Clin Infect Dis       Date:  2004-02-17       Impact factor: 9.079

9.  HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity.

Authors:  Souheil-Antoine Younes; Bader Yassine-Diab; Alain R Dumont; Mohamed-Rachid Boulassel; Zvi Grossman; Jean-Pierre Routy; Rafick-Pierre Sekaly
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

10.  An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection.

Authors:  J L Flynn; J Chan; K J Triebold; D K Dalton; T A Stewart; B R Bloom
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

View more
  113 in total

1.  Multifunctional CD4⁺ T cells in patients with American cutaneous leishmaniasis.

Authors:  A B B Macedo; J C Sánchez-Arcila; A O Schubach; S C F Mendonça; A Marins-Dos-Santos; M de Fatima Madeira; T Gagini; M I F Pimentel; P M De Luca
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

2.  Effector Phenotype of Plasmodium falciparum-Specific CD4+ T Cells Is Influenced by Both Age and Transmission Intensity in Naturally Exposed Populations.

Authors:  Michelle J Boyle; Prasanna Jagannathan; Katherine Bowen; Tara I McIntyre; Hilary M Vance; Lila A Farrington; Bryan Greenhouse; Felistas Nankya; John Rek; Agaba Katureebe; Emmanuel Arinaitwe; Grant Dorsey; Moses R Kamya; Margaret E Feeney
Journal:  J Infect Dis       Date:  2015-02-02       Impact factor: 5.226

3.  Use of antigen-specific interleukin-2 to differentiate between cattle vaccinated with Mycobacterium bovis BCG and cattle infected with M. bovis.

Authors:  Shelley G Rhodes; Lucy C McKinna; Sabine Steinbach; Gilly S Dean; Bernardo Villarreal-Ramos; Adam O Whelan; C Pirson; Gareth J Jones; Derek Clifford; H Martin Vordermeier
Journal:  Clin Vaccine Immunol       Date:  2013-10-30

4.  Clinical significance of interleukin-2/gamma interferon ratios in Mycobacterium tuberculosis-specific T-cell signatures.

Authors:  Franziska Suter-Riniker; Antonia Berger; Désirée Mayor; Pascal Bittel; Patricia Iseli; Thomas Bodmer
Journal:  Clin Vaccine Immunol       Date:  2011-06-01

Review 5.  Latent tuberculosis: what the host "sees"?

Authors:  Hannah P Gideon; JoAnne L Flynn
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

6.  Combinatorial Immunoprofiling in Latent Tuberculosis Infection. Toward Better Risk Stratification.

Authors:  Patricio Escalante; Tobias Peikert; Virginia P Van Keulen; Courtney L Erskine; Cathy L Bornhorst; Boleyn R Andrist; Kevin McCoy; Larry R Pease; Roshini S Abraham; Keith L Knutson; Hirohito Kita; Adam G Schrum; Andrew H Limper
Journal:  Am J Respir Crit Care Med       Date:  2015-09-01       Impact factor: 21.405

Review 7.  Diagnostic accuracy of IL-2 for the diagnosis of latent tuberculosis: a systematic review and meta-analysis.

Authors:  S Mamishi; B Pourakbari; M Teymuri; P-A Rubbo; E Tuaillon; A A Keshtkar; S Mahmoudi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-07-04       Impact factor: 3.267

8.  Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis.

Authors:  W P Drake; B W Richmond; K Oswald-Richter; C Yu; J M Isom; J A Worrell; G R Shipley
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2013-11-25       Impact factor: 0.670

9.  Reversion and conversion of Mycobacterium tuberculosis IFN-gamma ELISpot results during anti-tuberculous treatment in HIV-infected children.

Authors:  Tom G Connell; Mary-Ann Davies; Christine Johannisen; Kathryn Wood; Sandy Pienaar; Katalin A Wilkinson; Robert J Wilkinson; Heather J Zar; David Beatty; Mark P Nicol; Nigel Curtis; Brian Eley
Journal:  BMC Infect Dis       Date:  2010-05-27       Impact factor: 3.090

10.  Immunological memory transferred with CD4 T cells specific for tuberculosis antigens Ag85B-TB10.4: persisting antigen enhances protection.

Authors:  Darragh Duffy; Amina Dawoodji; Else Marie Agger; Peter Andersen; Jürgen Westermann; Eric B Bell
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.